In-Depth Analysis of the Investment Impact of the 'Personal Medical Insurance Cloud' Pilot Program on the Smart Health Industry Chain
Unlock More Features
Login to access AI-powered analysis, deep research reports and more advanced features

About us: Ginlix AI is the AI Investment Copilot powered by real data, bridging advanced AI with professional financial databases to provide verifiable, truth-based answers. Please use the chat box below to ask any financial question.
Related Stocks
Now let me prepare a detailed and professional investment analysis report for you:
National Healthcare Security Administration (NHSA) launched the ‘Personal Medical Insurance Cloud’ construction pilot from February to December 2024, which is a major strategic initiative in the field of medical insurance informatization. The pilot is based on the national unified medical insurance information platform to build provincial (municipal) personal medical insurance clouds, aiming to aggregate core data such as diagnosis and treatment, settlement, and pharmaceutical consumables usage from designated medical institutions, and connect with out-of-hospital health data from wearable devices, home intelligent monitoring devices, and physical examination institutions to achieve integration of in-hospital and out-of-hospital data [1].
| Data Type | Source | Application Scenario |
|---|---|---|
| Diagnosis and Treatment Data | Designated Medical Institutions | Clinical Decision Support, Disease Monitoring |
| Settlement Data | Medical Insurance Payment System | Cost Analysis, Medical Insurance Cost Control |
| Pharmaceutical Consumables Data | Medical Institutions | Medication Monitoring, Prescription Circulation |
| Out-of-Hospital Health Data | Wearable Devices, Physical Examination Institutions | Health Management, Chronic Disease Early Warning |
This architecture design marks the transformation of medical insurance data from ‘fragmented’ to ‘panoramic’, bringing unprecedented opportunities for revaluation of data asset value to the smart health industry chain [2].
The medical informatization market is in a new boom cycle driven by policies. The scale of the digital medical market is expected to reach 580 billion yuan in 2025, and is expected to exceed 1.2 trillion yuan by 2031 [3]. The scale of the medical big data analysis market is expected to exceed 420 billion yuan in 2025, with the main driving forces coming from the construction of the national health information platform promoted by the National Health Commission and the popularization of clinical decision support systems.
According to industry research data, major listed companies in the A-share medical informatization sector show a clear differentiation pattern:
| Company | Proportion of Medical Business | Business Characteristics | Investment Elasticity |
|---|---|---|---|
| Weining Health (300253) | 100% | Absolute Leader in Medical Informatization | High |
| Chuangye Huikang (300451) | 84% | Dual Drive of Public Health + Hospitals | High |
| Jiuyin Yinhai (002777) | 41% | Core Vendor in Medical Insurance Informatization | Medium-High |
| Heren Technology (300550) | 96% | Professional Vendor in Medical Informatization | Medium |
| Meditech (603990) | 100% | Leader in Anesthesia Informatization | Medium |
-
Policy-driven: Mandatory policy requirements such as the hierarchical evaluation of electronic medical record system function application levels, the standardized maturity evaluation of hospital information interconnection, and the hierarchical evaluation of hospital smart services are accelerating the informatization construction of medical institutions [6].
-
Demand recovery: After the relaxation of epidemic prevention and control, hospital operations and revenues are gradually returning to normal, and informatization budget expenditures are expected to resume growth.
-
Product upgrade: The new generation of cloud-based products (Hi-HIS, “Huikang Cloud 2.0”) brings a product upgrade cycle, and leading manufacturers are expected to benefit from the improvement of industry concentration.
The medical big data market presents a development pattern of coordinated development across multiple segmented fields:
| Segmented Field | 2024 Scale | 2025 Forecast | Growth Rate | Policy Sensitivity |
|---|---|---|---|---|
| Medical Data Analysis Platform | Approximately 120 billion yuan | Approximately 160 billion yuan | 33% | High |
| Medical Insurance Big Data | Approximately 80 billion yuan | Approximately 110 billion yuan | 38% | Very High |
| Clinical Decision Support | Approximately 60 billion yuan | Approximately 85 billion yuan | 42% | High |
| Health Management Big Data | Approximately 40 billion yuan | Approximately 55 billion yuan | 38% | Medium |
As the core data asset of the ‘Personal Medical Insurance Cloud’ construction, medical insurance big data has a growth rate of up to 38% and “very high” policy sensitivity, making it an investment direction worthy of key attention [7].
The medical big data industry chain includes:
- Upstream: Data collection and processing (medical informatization vendors, data middle-end construction)
- Midstream: Data analysis and mining (AI algorithms, machine learning platforms)
- Downstream: Application scenarios (clinical decision-making, medical insurance cost control, health management)
The construction of the ‘Personal Medical Insurance Cloud’ will drive the release of data value across the entire industry chain, particularly benefiting enterprises with the following capabilities:
- Multi-source heterogeneous data integration capability
- AI application capability in medical scenarios
- Privacy computing and data security capability
The market size of China’s smart wearable health device industry reached 61.5 billion yuan in 2024, with a compound annual growth rate (CAGR) of 14.7% from 2019 to 2024 [8]. The market size is expected to reach 120 billion yuan in 2025, and the shipment volume of wrist-worn devices reached 61.16 million units in 2024, a year-on-year increase of 19.3%.
| Segmented Field | 2024 Scale | 2025 Forecast | Year-on-Year Growth | Policy Sensitivity |
|---|---|---|---|---|
| Smart Watch | Approximately 28 billion yuan | Approximately 35 billion yuan | 25% | Medium |
| Smart Bracelet | Approximately 12 billion yuan | Approximately 15 billion yuan | 25% | Medium |
| Medical-Grade Monitoring Devices | Approximately 15 billion yuan | Approximately 20 billion yuan | 33% | High |
| Rehabilitation Monitoring Devices | Approximately 6.5 billion yuan | Approximately 8.5 billion yuan | 31% | High |
The global smart wearable health device market presents a pattern of “international giants leading + domestic brands rising”:
| Competitive Echelon | Representative Enterprises | Market Positioning | Competitive Advantages |
|---|---|---|---|
| International High-End | Apple, Garmin | Medical-grade Functions, Ecological Synergy | Technology, Brand, Ecology |
| Domestic Leading | Huawei, Xiaomi | Mass Market, Cost-Effectiveness | Channels, Localized Services |
| Professional Segmentation | Lifesense Medical | Medical-Grade Monitoring | Product Innovation, Professional Segmentation |
Huawei continues to lead industry growth, has ranked first in China’s market shipment volume for five consecutive years, with a year-on-year shipment growth rate of 34.6%, ranking first globally [9].
-
Value of out-of-hospital data entry: The ‘Personal Medical Insurance Cloud’ clearly includes wearable device data in the out-of-hospital health data system, making device manufacturers an important entry point in the medical insurance data ecosystem.
-
Medical-grade product upgrade: Driven by policies, medical-grade devices with disease screening, early warning, monitoring, and treatment capabilities have better market prospects.
-
Eco-integration trend: Wearable devices are breaking industry boundaries, forming a cross-border integrated ecosystem of ‘device + data + service’, and innovating business models through linkage with insurance and telemedicine platforms.
| Investment Theme | Core Logic | Benefiting Segments | Key Targets |
|---|---|---|---|
| Medical Insurance Data Infrastructure | Expansion of unified medical insurance platform | Medical IT, Data Middle-End | Weining Health, Chuangye Huikang |
| Out-of-Hospital Data Integration | Wearable Device Access | Wearable Devices, Data Platforms | Huawei, Xiaomi, Lifesense Medical |
| Intelligent Clinical Decision-Making | Popularization of AI-Assisted Diagnosis | AI Medical, Medical Big Data | Medical IT Enterprises + AI Enterprises |
| Health Management Closed Loop | Connection of In-Hospital and Out-of-Hospital Data | Health Management Platforms, Insurance Companies | Wantai Information, Ping An Good Doctor |
- Medical informatization policy advancement falls short of expectations
- Uncertain progress of medical insurance payment policy reform
- Changes in data security and privacy protection policies
- Fluctuations in hospital informatization budget expenditures
- Decline in gross profit margin due to intensified industry competition
- Long payment collection cycle for medical IT enterprises
- Accuracy and security of AI diagnosis
- Progress of unifying medical data interconnection standards
- Technical barriers to connecting wearable device data with medical systems
Based on the above analysis, it is recommended to focus on the following investment targets:
| Target | Ticker | Core Logic | Risk Level | Investment Rating |
|---|---|---|---|---|
| Weining Health | 300253.SZ | Absolute leader in medical informatization, leading in cloud transformation | Medium | Buy |
| Chuangye Huikang | 300451.SZ | Public health leader, “Huikang Cloud 2.0” product cycle | Medium | Buy |
| Jiuyin Yinhai | 002777.SZ | Core vendor in medical insurance informatization | Medium | Overweight |
| Huawei Ecosystem | - | Leading position in wearable device market | Low | Watch |
| Lifesense Medical | 300562.SZ | Professional vendor of medical-grade wearable devices | Medium-High | Watch |
The ‘Personal Medical Insurance Cloud’ pilot program is a milestone event in the field of medical insurance informatization, which will profoundly reshape the competitive landscape and value distribution of the smart health industry chain. Three key segments: medical informatization, medical big data, and wearable devices will usher in historic development opportunities.
- Medical Informatization: Prioritize industry leaders such as Weining Health and Chuangye Huikang, and pay attention to incremental opportunities brought by product upgrades and cloud transformation [10]
- Medical Big Data: Focus on the sub-tracks of medical insurance big data and clinical decision support, which have high policy sensitivity
- Wearable Devices: Focus on the medical-grade monitoring device segment, and the ecological advantages of leading manufacturers such as Huawei and Xiaomi
[1] National Healthcare Security Administration (NHSA). Policy Interpretation of the ‘Personal Medical Insurance Cloud’ Construction Pilot. https://www.nhsa.gov.cn/art/2025/7/24/art_14_17369.html
[2] China Business Industry Research Institute. 2025 China Internet Medical Industry Chain Map and Investment Layout Analysis. http://gpos.cn/News/IndustryNewsArticle/b5d49101-3771-4ca6-9b3a-a831caed4f77
[3] CSDN. 2025 Panoramic Analysis of China’s Digital Medical Industry Chain. https://blog.csdn.net/garyond/article/details/150419347
[4] Tianfeng Securities. In-Depth Report on Chuangye Huikang (300451). https://pdf.dfcfw.com/pdf/H3_AP202302101582992140_1.pdf
[5] Zheshang Securities. Medical IT Industry Recovery, Hi-HIS and CTasy Create Incremental Value. https://pdf.dfcfw.com/pdf/H3_AP202311041608512949_1.pdf
[6] Great Wall Guorui Securities. Medical Informatization Industry Research Report. https://pdf.dfcfw.com/pdf/H3_AP202304221585716394_1.pdf
[7] LeadLeo Research Institute. 2023 Overview of China’s Wearable Medical Device Industry. https://pdf.dfcfw.com/pdf/H3_AP202308021593156935_1.pdf
[8] Huaon Industry Research Institute. 2025 Status and Trend Analysis of Global and China’s Smart Wearable Health Device Industry. https://www.huaon.com/channel/trend/1134446.html
[9] IDC. 2024 Global and China Wrist-Worn Device Market Data. https://www.idc.com/
[10] CITIC Securities. Policy Guides Digital and Intelligent Innovation Across the Entire Pharmaceutical Industry Chain. https://stcn.com/article/detail/1712420.html
Insights are generated using AI models and historical data for informational purposes only. They do not constitute investment advice or recommendations. Past performance is not indicative of future results.
About us: Ginlix AI is the AI Investment Copilot powered by real data, bridging advanced AI with professional financial databases to provide verifiable, truth-based answers. Please use the chat box below to ask any financial question.
